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In November 2010, the CDC released updated guidelines 
for the prevention of early onset neonatal GBS infections.1  
This update replaces the 2002 CDC guidelines.  Due to 
efforts to decrease GBS related disease, the incidence of 
early-onset GBS disease in the newborn has decreased 
significantly from 1.7 cases per 1000 live births to 0.34-
0.37 cases per 1000 live births.   Because rates of maternal 
colonization remain unchanged since the 1970s, we need 
to continue to be vigilant in our efforts to prevent GBS 
disease. Therefore, the updated guidelines, endorsed by 
ACOG and AAP, continue to recommend screening of 
all pregnant women between 35 and 37 weeks but they 
clarify many issues that were left unaddressed in the 2002 
guidelines, including new methods for identifying GBS, a 
new definition of GBS bacteriuria, clarified screening and 
treatment algorithms for women with preterm labor and 
preterm premature rupture of membranes (PPROM), dosing 
information of penicillin,  revised prophylaxis regimens for 
penicillin allergic women as well as a new algorithm for 
management of potentially affected newborns. We review 
these changes, as well as unchanged key aspects of the 2002 
guidelines.
Identifying GBS
Proper identification of GBS first relies upon correct 
collection techniques. Specimens should be collected from 
the inside of the lower vagina (introitus) and through the 
anal sphincter. The same swab can be used, or 2 different 
swabs can be used, if desired. However, they should be 
treated as 1 sample.  A speculum should not be used 
during the collection. If lab processing is not immediately 
available, transport media can be used for samples. The 
highest specificity occurs if the sample is stored at 4o and 
is processed within 24 hours of collection. Typically after 
enrichment, GBS is isolated on blood agar plates and then 
identified by the CAMP test or by a latex agglutination 
assay.  If chromogenic media is used, a negative result 
must be confirmed by subculturing to an appropriate agar 
plate or the media can be directly tested for GBS.2  The 
CDC recommends that laboratories report GBS results 
in concentrations of ³ 104 colony forming units/ml from 
urine specimens of pure or mixed organism cultures. 
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However, many labs report GBS at lower concentrations.  
For example, the University of Iowa Clinical Microbiology 
lab reports any GBS isolate in urine culture in any 
reproductive age woman regardless of colony count 
according to recommendations from the American Society 
for Microbiology.  Any urine culture reported as GBS 
positive, regardless of the colony count, should be considered 
positive as any positive urine culture is considered a marker 
of heavy GBS colonization.  Therefore, any GBS positive urine 
culture regardless of colony count should be considered GBS 
positive for the entire pregnancy and the pregnant woman 
should receive intrapartum antibiotic prophylaxis.3
Antibiotic sensitivities should be performed on any 
GBS isolate from urine or rectovaginal swab if the patient 
is known to be allergic to penicillin and is at high risk 
of anaphylaxis.  The CDC 2010 guidelines clearly define 
“high risk of anaphylaxis” as: a history of anaphylaxis, 
angioedema, respiratory distress or urticaria following the 
administration of a penicillin or a cephalosporin.
Susceptibility testing must include testing for inducible 
clindamycin resistance, such as a D zone test. In the “D zone 
test,” or double-disk diffusion method, a clindamycin disk 
is away from the edge of an erythromycin disk.  The sample 
is incubated overnight and strains that have inducible 
resistance will show flattening of the clindamycin zone in 
the area next to the erythromycin disc “D zone.” 
While the 2010 guidelines acknowledge some of the 
limitations of identification of GBS by PCR based nucleic 
acid amplification tests (NAAT), including test complexity, 
costs, availability, and staffing requirements, the updated 
guidelines do expand the options for the laboratory to 
include NAAT.  NAAT directly from the swab may be 
used for women at term with an unknown GBS status who 
have no other risk factors. If GBS is identified by NAAT, 
then intrapartum antibiotic prophylaxis (IAP) should 
be given. However, if a patient develops any risk factor, 
then IAP should be given regardless of the NAAT results. 
For prenatal NAAT tests, the test must be done from an 
enrichment broth.  Availability for this testing in the state 
of Iowa is limited.  At the University of Iowa, a rapid PCR 
technique to detect GBS is limited and is only available as a 
mail out assay.  
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Screening and Treatment Algorithms 
(See Figure 1)
With regards to screening, all pregnant women should 
be screened at 35-37 weeks.  The only exceptions are women 
who had GBS isolated from urine at any time in the current 
pregnancy or who had a previous infant with invasive GBS 
disease.  As previously stated, a pregnant woman with a 
urine culture positive for GBS regardless of the colony count 
and gestational age of collection should be considered GBS 
colonized.  While these women do not need third trimester 
screening, they should receive intrapartum antibiotic 
prophylaxis.  IAP should be given to these GBS bacteruric 
patients even if repeat urine cultures are negative.  
With regard to GBS urinary tract infection (UTI), primary 
treatment for GBS UTI should occur if the colony count is 
greater than 10,000 colony forming units/mL.  If the patient 
is asymptomatic and has a colony count less than 10,000 
colony forming units/mL, then they do not need to be 
primarily treated for the GBS UTI.  Women should also be 
screened if they experience preterm labor or PPROM.  Any 
woman, who screens positive for GBS, should be given IAP 
with the exception of women who are having a cesarean 
section performed prior to the onset of labor and rupture 
of membranes.  Nevertheless, these women still should be 
screened in case of labor or ROM occurs before the planned 
c-section. Unless they have a urinary tract infection, these 
women should not be given be antibiotics to clear the GBS 
infection. 
IAP is indicated if the GBS status is unknown at the 
onset of labor and at least one of the following occur: 
delivery will occur <37 weeks gestation, ROM ³ 18 hours, 
intrapartum temperature ³ 100.4o, and/or a positive GBS 
result by intrapartum nucleic acid amplification tests. The 
new guidelines clearly highlight that GBS screening should 
be performed and that prophylaxis is indicated if these 
patients are likely to deliver and should be discontinued 
if it is decided that the woman is not in true labor. For 
women who experience PPROM, GBS screening should be 
performed and latency antibiotics should be given if they 
are not in labor. If they are in labor, then GBS prophylaxis 
should be administered. IAP is not indicated solely for the 
reason of colonization by GBS in a previous pregnancy 
or GBS bacteriuria in a previous pregnancy. Regardless 
of intrapartum risk factors, IAP is also not indicated if a 
negative rectovaginal screening culture was obtained in 
late gestation of the current pregnancy.  A vaginal-rectal 
GBS screening result is valid for 5 weeks if done prior to 35 
weeks gestation. After 35 weeks, GBS screening does not 
need to be repeated.
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Figure 1: GBS Screening and Treatment Algorithm 
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900mg IV Q8h until delivery should be used if their GBS 
is susceptible to clindamycin and erythromycin, and the 
D-zone test was negative if the isolate was erythromycin 
resistant.  Erythromycin is no longer listed as an alternative 
for penicillin-allergic women.  For a penicillin-allergic, high 
anaphylaxis risk women with unknown GBS sensitivity 
results, then vancomycin, 1 gram IV every 12 hours until 
delivery should be administered. Vancomycin should be 
used prudently because it is not as effective for IAP as 
clindamycin and is a “drug of last resort” for gram positive 
bacterial infections.  
Regarding the duration of IAP with respect to 
delivery, there is insufficient data regarding the timing 
of intrapartum procedures, such as amniotomy for labor 
progression, and length of IAP administration.  Ideally, IAP 
should be administered at least 4 hours before delivery.  Yet 
an obstetrically necessary procedure, such as amniotomy 
for the placement of a fetal scalp electrode in the setting of 
nonreassuring fetal heart tones, should not be delayed to 
achieve the 4 hours of IAP. 
Prophylaxis regimens 
(See Figure 2)
Penicillin G remains the drug of choice for IAP; 5 million 
units should be given IV, then 2.5 to 3 million units given 
every 4 hours until delivery. This range provides flexibility 
based on what formulation is available.  The same degree 
of protection is provided by this range. Ampicillin can 
also be given as 2 grams IV followed by 1 gram IV every 
4 hours until delivery.  In the case of women who are 
allergic to penicillin and are not at high risk for anaphylaxis 
such as those who do not  have a history of anaphylaxis, 
angioedema, respiratory distress syndrome, or urticaria 
with penicillin or cephalosporin administration, then 
cefazolin (2g IV initial dose, then 1 g IV every 8 hours 
until delivery) is the antibiotic of choice. Cefazolin has 
similar pharmacokinetics to penicillin and concentrates 
well in amniotic tissues. In contrast, clindamycin does 
not concentrate well in fetal tissue or amniotic fluid. If a 
woman is at high risk for anaphylaxis, then clindamycin 
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Figure 2:  Intrapartum Antibiotic Prophylaxis Regimen Algorithm 
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Secondary Prevention in Newborns
The 2010 guidelines provide much more guidance for 
the treatment of newborns and aim to reduce unnecessary 
evaluations.  The treatment algorithm for newborns 
applies regardless of whether the mother received IAP. The 
updated guidelines are now based on the child’s clinical 
appearance and gestational age, as well as maternal factors 
such as chorioamnionitis, prolonged rupture of membranes, 
and adequacy of the IAP.  The definition of adequate IAP 
has also been clarified; adequate IAP is defined as the 
administration of penicillin, ampicillin, or cefazolin for at 
least 4 hours prior to delivery. Any other agent or duration 
is considered inadequate. 
If a mother had an indication for IAP, but did not receive 
any or only inadequate IAP, the treatments have changed 
from the 2002 guidelines. For a well-appearing child born ³ 
37 weeks and the membranes were ruptured for less than 18 
hours, only 48 hour observation is required; no additional 
diagnostic testing is necessary.
A full evaluation should be performed for any infant 
with signs of sepsis and the mother did not receive IAP. 
A full evaluation includes complete blood count with 
differential and platelets, blood culture, chest radiograph (if 
respiratory abnormalities are present), and lumbar puncture 
(if the patient is stable enough to tolerate procedure 
and sepsis is suspected). Therapy for the infant should 
include antimicrobial agents active against GBS (including 
intravenous ampicillin) as well as other organisms that 
might cause neonatal sepsis, such as E.Coli. This is generally 
a combination of ampicillin and gentamicin, but antibiotic 
resistance patterns at your hospital should be considered.
In the setting of maternal chorioamnionitis, a limited 
evaluation and antibiotic therapy should be performed.  A 
limited evaluation includes a blood culture at birth and a 
complete blood count with differential at birth and/or 6-12 
hours of life.  A limited evaluation is also indicated if birth 
occurs < 37 weeks or the duration of membrane rupture is ≥ 
18 hours.
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Category Key Updates to 2002 Recommendations
Screening for GBS ·	 Guidance regarding to cesarean delivery before labor and no ROM is 
applied to all gestational ages
·	 New screening protocols with PCR (NAAT) based techniques
Screening in the setting of threatened pre-
term labor
·	 Separate algorithms for spontaneous preterm labor and PPROM
·	 Discontinuation of GBS prophylaxis if not truly in labor
·	 PPROM latency antibiotic regimens including Ampicillin x 48 hours are 
adequate for GBS prophylaxis.  Yet, oral antibiotics alone not adequate.
GBS Specimen Processing ·	 In clindamycin susceptible, erythromycin resistant GBS isolates, inducible 
clindamycin resistance (D-Zone) testing should be performed.
·	 If available, clarified use of PCR (NAAT) based techniques
·	 Labs should report GBS in urine cultures in concentrations ≥ 104 cfu/mL
Intrapartum Antibiotic Prophylaxis ·	 Definition for high risk for anaphylaxis clarified as a history of 
anaphylaxis, angioedema, respiratory distress or urticaria after penicillin 
or a cephalosporin.
·	 Dosing of penicillin G to be 2.5-3.0 million units IV every 4 hours for 
appropriate drug levels and allow flexibility in penicillin G formulations.
·	 Erythromycin is NOT an alternative antibiotic in penicillin-allergic 
women.
Secondary Prevention of GBS in Neonates ·	 Recommendations apply to all newborns.
·	 Adequate IAP strictly defined as ≥ 4 hours of IV penicillin, ampicillin, or 
cefazolin.
·	 Well appearing infants with moms with indication for IAP, but did 
not receive IAP can be observed for ≥ 48 hours unless < 37 weeks or  ≥ 
18 hours of membrane rupture à limited evaluation and ≥ 48 hours 
observation
·	 Well appearing infants born between 35-36 weeks and mothers received 
IAP do not require diagnostic evaluations.
Table 1:  2010 CDC Updates to the 2002 CDC Group B Strep Recommendations
Summary
The 2010 changes to the 2002 guidelines are summarized 
in Table 1.  Although the incidence of early-onset 
invasive GBS disease in newborns is overall low, the high 
clindamycin and erythromycin resistance, unchanged GBS 
colonization rates, and higher early-onset GBS disease in 
different racial populations will require Iowa obstetric and 
pediatric providers to continue to be vigilant in applying 
these guidelines.  The knowledge and implementation of 
these updated guidelines will help improve the health of 
Iowa’s moms and babies.
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